Corient Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Corient Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.53M	Buy	5,448 +125	+2%	+$36K	0.11%	157
2022 Q2	$1.5M	Buy	5,323 +695	+15%	+$186K	0.11%	165
2022 Q1	$1.21M	Buy	4,628 +769	+20%	+$183K	0.08%	216
2021 Q4	$848K	Buy	3,859 +694	+22%	+$135K	0.06%	262
2021 Q3	$574K	Sell	3,165 -462	-13%	-$90.2K	0.04%	331
2021 Q2	$732K	Buy	3,627 +191	+6%	+$40K	0.05%	272
2021 Q1	$738K	Buy	3,436 +142	+4%	+$31.2K	0.06%	244
2020 Q4	$779K	Buy	3,294 +242	+8%	+$55.5K	0.08%	206
2020 Q3	$830K	Sell	3,052 -227	-7%	-$62.6K	0.1%	183
2020 Q2	$952K	Buy	3,279 +258	+9%	+$69.9K	0.12%	165
2020 Q1	$719K	Buy	3,021 +358	+13%	+$82.1K	0.11%	158
2019 Q4	$583K	Buy	2,663 +63	+2%	+$12.8K	0.07%	257
2019 Q3	$441K	Buy	2,600 +542	+26%	+$95.9K	0.06%	279
2019 Q2	$377K	Sell	2,058 -601	-23%	-$105K	0.06%	275
2019 Q1	$489K	Buy	2,659 +1,260	+90%	+$233K	0.08%	222
2018 Q4	$232K	Buy	+1,399	New	+$242K	0.04%	285

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Corient Capital Partners's VRTX Position: Q3 2022 in Review

Corient Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q3 2022, buying an estimated $36K and bringing the position to 5,448 shares worth $1.53M. The position accounts for 0.11% of the portfolio, ranked #157.

Corient Capital Partners first reported a position in VRTX in Q4 2018 and has held it in 16 quarters since. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Corient Capital Partners held 5,448 shares of Vertex Pharmaceuticals worth $1.53M as of Q3 2022.
Corient Capital Partners bought 125 Vertex Pharmaceuticals shares in Q3 2022, an estimated $36K.
Vertex Pharmaceuticals made up 0.11% of Corient Capital Partners's portfolio in Q3 2022, its #157 holding.
Corient Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 16 quarters since.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.